Clinical Status and Optimal Use of Amifostine

ONCOLOGY

Volumn 13, Issue 1, 1999, Pages 47-59

  Capizzi, Robert L ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; ALKYLATING AGENT; AMIFOSTINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; MERCAPTAMINE; PACLITAXEL; PLATINUM COMPLEX;

BONE MARROW PURGING; CANCER STAGING; CELL PROTECTION; CLINICAL TRIAL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SCREENING; DRUG TOLERABILITY; DRUG UTILIZATION; FEMALE; HUMAN; LEUKEMIA CELL; META ANALYSIS; OVARY CANCER; RADIATION PROTECTION; REVIEW;

AMIFOSTINE; ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CLINICAL TRIALS, PHASE III; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEUKEMIA; MULTICENTER STUDIES; OVARIAN NEOPLASMS; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; TUMOR CELLS, CULTURED;

EID: 0032933401     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Bertino JR: "Rescue" techniques in cancer chemotherapy: Use of leucovorin and other rescue agents after methotrexate treatment. Semin Oncol 4(2):203-216, 1977.
2. Shapiro WR: Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular, and lumbar infections. N Engl J Med 293:161, 1975.
3. Mesnex (mesna), in Arky R (ed): Physician's Desk Reference. Montvale, New Jersey, Medical Economics, 1998.
4. Zinecard (dexrazoxone) in Arky R (ed): Physician's Desk Reference. Montvale, New Jersey, Medical Economics, 1998.
5. Patt HM, Tyree EB, Straube RL, et al: Technical papers: Cysteine protection against X irradiation. Science 110:213-214, 1949.
6. Shaw LM, Turrisi AT III, Glover DJ, et al: Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys 12:1501-1504, 1986.
7. Shaw LM, Glover DJ, Turrisi A, et al: Pharmacokinetics of WR-2721. Pharmacol Ther 39:195-201, 1988.
8. Shaw L, Bonner H, Nakashima H, et al: Pharmacokinetics of amifostine in cancer patients: Evidence for saturable metabolism (abstract). Proc Am Soc Clin Oncol 13:144, 1994.
9. Shaw LM, Bonner HS, Brown DQ: Metabolic pathways of WR-2721 (Ethyol, amifostine) in the balb/c mouse. Drug Metab Dispos 22:895-902, 1994.
10. Calabro-Jones PM, Aguilera JA, Ward JF, et al: Uptake of WR-2721 derivatives by cells in culture: Identification of the transported form of the drug. Cancer Res 48:3634-3640, 1988.
11. Smoluk GD, Fahey RC, Calabro-Jones PM, et al: Radioprotection of cells in culture by WR-2721 and derivatives: Form of the drug responsible for protection. Cancer Res 48:3641-3647, 1988.
12. Calabro-Jones PM, Fahey RC, Smoluk GD, et al: Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol Phys 47:23-27, 1985.
13. Zhang X, Lai P, Taylor Y: Differential radioprotection of cultured human diploid fibroblasts and fibrosarcoma cells by WR-1065. Radiat Oncol Biol Phys 21:128, 1990.
14. Myers CE, McGuire WP, Liss RH, et al: Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response. Science 197:165-167, 1997.
15. DeNeve WJ, Everett CK, Suminski JE, et al: Influence of WR-2721 on DNA cross-linking by nitrogen mustard in normal mouse bone marrow and leukemia cells in vivo. Cancer Res 48:6002-6005, 1988.
16. Treskes M, Holwerda U, Nijtmans L, et al: Modulation of cisplatin and carboplatin with WR-2721, molecular aspects. 7th Conf Chem Mod Cancer Treat , pp 322-323, 1991.
17. Treskes M, Holwerda U, Nijtmans LGJ, et al: The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278. Cancer Chemother Pharmacol 29(6):467-470, 1992.
18. El-Ghissassi F, Verhaegh G, Hainaut P: Modulation of wild-type p53 protein activity by the aminothiol amifostine (abstract). Proc Am Soc Clin Oncol 16:543a, 1997.
19. Capizzi RL: Amifostine: The preclinical basis for broad-spectrum spectrum cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 23:2-17, 1996.
20. Glover D, Glick J, Weiler C, et al: WR-2721 and high-dose cisplatin: An active combination in the treatment of metastatic melanoma. J Clin Oncol 5(4):574-578, 1987.
21. Glover DJ, Glick JH, Weiler C, et al: WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II trial. J Clin Oncol 4:584-588, 1986.
22. Kemp G, Rose P, Lurain J, et al: Amifostine pretreatment for protection against cyclophosphamide- and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112, 1996.
23. Schiller JH, Storer B, Berlin J, et al: Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: A report of high response rates and prolonged survival. J Clin Oncol 14:1913-1921, 1996.
24. Planting AST, Catimel G, de Mulder PHM, et al: Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. J Clin Oncol, 1998 (in press).
25. Ferris TF, DuBose TD, Jr, Falk RJ, et al: Nephrology and hypertension, in Goldman L (ed): Medical Knowledge Self-Assessment Program, 10th ed, pp 605-645. Philadelphia, American College of Physicians, 1994
26. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976.
27. Alberts DS, Green S, Hannigan EV, et al: Improved therapeutic index of carboplatin plus cyclophosphamide vs cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10:706-717, 1992.
28. Adams M, Kerby IJ, Rocker I, et al: A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. Acta Oncol 28:57-60, 1989.
29. Wiltshaw E: Ovarian trials at the Royal Marsden. Cancer Treat Rep 12:67-71, 1985.
30. Reece PA, Stafford I, Russell J, et al: Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: Relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 5:304-309, 1987.
31. Mangioni C, Bolis S, Pecorelli S, et al: Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst 81:1464-1471, 1989.
32. Anderson H, Wagstaff J, Crowther D, et al: Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer. Eur J Cancer Clin Oncol 4:1471-1479, 1988.
33. Neijt JP, ten Bokkel Huinink WW, Van Der Burg MEL, et al: Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 5:1157-1168, 1987.
34. Goren MP, Wright RK, Horowitz ME: Cumulative renal tubular damage associated with cisplatin nephrotoxicity. Cancer Chemother Pharmacol 18:69-73, 1986.
35. Fjeldborg P, Sorensen J, Helkjaer PE: The long-term effect of cisplatin on renal function. Cancer 58:2214-2217, 1986.
36. Dentino M, Luft FC, Yum MN, et al: Long-term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 41:1274-1281, 1978.
37. Groth S, Nielson H, Srenson JB, et al: Acute and long-term nephrotoxicity of cis-platinum in man. Cancer Chemother Pharmacol 17:191-196, 1986.
38. Brock J, Alberts DS: Safe, rapid administration of cisplatin in the outpatient clinic. Cancer Treat Rep 70:1409-1414, 1986.
39. Hrushesky WJM, Shimp W, Kennedy BJ: Lack of age-dependent cisplatin nephrotoxicity. Am J Med 76:579-584, 1984.
40. Vogelzang NJ, Torkelson JL, Kennedy BJ: Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 56:2765-2770, 1985.
41. Mollman JE, Glover DJ, Hogan WM, et al: Cisplatin neuropathy: Risk factors, prognosis, and protection by WR-2721. Cancer 61:2192-2195, 1988.
42. Shpall EJ, Stemmer SM, Hami L, et al: Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 83:3132-3137, 1994.
43. Stemmer SM, Shpall EJ, Jones RB, et al: Amifostine (WR-2721) shortens the engraftment time of 4-hydroperoxycyclophosphamide (4-HC) purged bone marrow in lymphoma patients receiving high-dose chemotherapy (HDC) with autologous bone marrow support (ABMS). Blood 80(10; suppl 1):70a, 1992.
44. Douay L, Hu C, Giarratana MC, et al: Amifostine improves the antileukemic therapeutic index of mafosfamide: Implications for bone marrow purging. Blood 86(7):2849-2855, 1995.
45. Valeriote F, Tolen S: Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 42:4330-4331, 1982.
46. Treskes M, Boven E, Loosdrecht AA, et al: Effects of the modulating agent WR-2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur J Cancer 30:183-187, 1994.
47. Taylor CW, Wang LM, List AF, et al: Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. Eur J Cancer 33:1693-1698, 1997.
48. Green D, Wright A, Schein PS, et al: WR-2721 chemoprotection of doxorubicin toxicity in mice (abstract). Proc Am Assoc Cancer Res 33:490, 1992.
49. Patchen ML, MacVittie TJ: Granulocyte colony-stimulating factor and amifostine (Ethyol) synergize to enhance hemopoietic reconstitution and increase survival in irradiated animals. Semin Oncol 21:26-32, 1994.
50. MacVittie TJ, Brandenburg R, Farese AM, et al: Enhanced recovery from supralethal radiation exposure using combined modality WR-2721 plus recombinant human (rh) G-CSF (abstract). Proc Am Assoc Cancer Res 33:505, 1992.
51. Mercer V, Anderson H, Habboubi N, et al: A phase III randomised study of carboplatin and amifostine versus carboplatin and G-CSF in patients with inoperable non-small-cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 16:474a, 1997.
52. Dorr RT, Lagel K, McLean S: Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitro. Eur J Cancer 32A(suppl4):S21-25, 1996.
53. De Lena M, Catino A, Calabrese P, et al: Amifostine (AMF) protects against doxorubicin (D) toxicity with preservation of therapeutic activity in advanced breast cancer (ABC) patients (abstract). Proc Am Soc Clin Oncol 17:137a 1998.
54. Nici L, Kuhn C, Calabresi P: Modulation of bleomycin-induced pulmonary toxicity in the hamster by the antioxidant, amifostine. Cancer, 1998 (in press).
55. Yuhas JM, Spellman JM, Culo F: The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 3:211-216, 1980.
56. Yuhas JM, Storer JB: Differential chemoprotection of normal and malignant tissues. J Natl Cancer Inst 42:331-335, 1969.
57. Wasserman TH, Phillips TL, Ross G, et al: Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721. Cancer Clin Trials 4:3-6, 1981.
58. Milas L, Hunter N, Reid BO: Protective effects of WR-2721 against radiation-induced injury of murine gut, testis, lung, and lung tumor nodules. Int J Radiat Oncol Biol Phys 8:535-538, 1982.
59. Liu T, Liu Y, He S, et al: Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 69:2820-2825, 1992.
60. Tanaka Y, Akagi K, Hasegawa T, et al: Studies on the radioprotective effects of YM-08310 (WR-2721): Part 1. Radioprotective effects of YM-08310 on normal and malignant tissues in mice. Nippon Igaku Hoshasen Gakkai Zasshi 43:700-709, 1983.
61. Büntzel J, Kuttner K, Frohlich D, et al: Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol 9:505-509, 1998.
62. Brizel D, Sauer R, Wannenmacher M, et al: Randomized phase III trial of radiation ± amifostine in patients with head and neck cancer (abstract). Proc Am Soc Clin Oncol 17:386a, 1998.
63. McDonald S, Meyerowitz C, Smudzin T, et al: Amifostine preserves the salivary gland function during irradiation of the head and neck. Eur J Cancer 31a(suppl 5):415, 1995.
64. Meagher RC, Rothman SA, Paul P, et al: Purging of small-cell lung cancer cells from human bone marrow using ethiofos (WR-2721) and light-activated merocyanine 540 phototreatment. Cancer Res 49:3637-3641, 1989.
65. List AF, Heaton R, Glinsmann-Gibson B, et al: Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin Oncol 23(4; suppl 8):58-63, 1996.
66. List AF, Brasfield F, Heaton R, et al: Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 90:3364-3369, 1997.
67. Raza A, Andric T, Oawi LL, et al: Combination of pentoxifylline (PTX), ciprofloxacin (Cipro), dexamethasone (PCD) with amifostine improves ineffective hematopoiesis in 70% of patients with myelodysplastic syndromes (MDS) (abstract). Blood 90:84a, 1997.
68. deCastro CM, Gockerman JP, Moor JO, et al: Preliminary results of a phase II study of amifostine for patients with myelodysplastic syndrome (abstract). Blood 90:286b, 1997.
69. Nagy B, Dale PJ, Grdina DJ: Protection against cis-diamminedichloroplatinum cytotoxicity and mutagenicity in V79 cells by 2-[(aminopropyl)amino]ethanethiol. Cancer Res 46:1132-1135, 1986.
70. Nagy B, Grdina DJ: Protective effects of 2-[(aminopropyl)amino] ethanethiol against bleomycin and nitrogen mustard-induced mutagenicity in V79 cells. Int J Radiat Oncol Biol Phys 12:1475-1478, 1986.
71. Sigdestad CP, Treacy SH, Knapp LA, et al: The effect of 2-[(aminopropyl)amino] ethanethiol (WR-1065) on radiation induced DNA double strand damage and repair in V79 cells. Br J Cancer 55:477-482, 1987.
72. Shigematsu N, Dale P, Schwartz J, et al: Spermine and the disulfide WR-33278 protect against radiation-induced cell killing and mutagenesis (abstract). Radiat Res 167:32-33, 1993.
73. Grdina DJ, Shigematsu N, Dale P, et al: Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anticytotoxic and antimulagenic mechanisms of action. J Carcinogenesis 16(4):767-774, 1995.
74. Kataoka Y, Perrin J, Hunter N, et al: Amifostine protects against cyclophosphamide and cisplatin-induced mutagenesis without affecting therapeutic effectiveness. Eur J Cancer 31a(suppl 5):110, 1995.
75. Kataoka Y, Perrin J, Hunter N, et al: Antimutagenic effects of amifostine: Clinical implications. Semin Oncol 23(4; suppl 8):53-57, 1996.
76. Milas L, Hunter N, Stephens LC, et al: Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 44:5567-5569, 1984.
77. Bhatia S, Robison LL, Oberlin O, et al: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334:745-751, 1996.
78. DiPaola RS, Rodriguez R, Goodin S, et al: Amifostine and dose intense paclitaxel in patients with advanced malignancies. Cancer Ther 1:11-17, 1998.
79. Betticher DC, Anderson H, Ranson M, et al: Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: A randomised phase II study. Br J Cancer 72(6):1551-1555, 1995.
80. Budd GT, Ganapathi R, Adelstein DJ, et al: Randomized trial of carboplatin plus amifostine vs carboplatin alone in patients with advanced solid tumors. Cancer 80:1134-1140, 1997.